Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation

详细信息    查看全文

• 作者：Ja Seong Bae ; Yourha Kim ; Sora Jeon ; Se Hee Kim ; Tae Jung Kim…
• 关键词：Thyroid cancer ; BRAF V600E ; Telomerase reverse transcriptase ; Anaplastic lymphoma kinase ; Iodine ; 131
• 刊名：Diagnostic Pathology
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：11
• 期：1
• 全文大小：1,237 KB
• 参考文献：1.Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184–99. doi:10.​1038/​nrc3431 .PubMedCentral CrossRef PubMed
  2.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.​3322/​caac.​20107 .CrossRef PubMed
  3.Toniato A, Boschin I, Casara D, Mazzarotto R, Rubello D, Pelizzo M. Papillary thyroid carcinoma: factors influencing recurrence and survival. Ann Surg Oncol. 2008;15(5):1518–22. doi:10.​1245/​s10434-008-9859-4 .CrossRef PubMed
  4.Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418–28.CrossRef PubMed
  5.Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, et al. Thyroid carcinoma. J Natl Compr Canc Netw. 2010;8(11):1228–74.PubMed
  6.Melck AL, Yip L, Carty SE. The utility of BRAF testing in the management of papillary thyroid cancer. Oncologist. 2010;15(12):1285–93. doi:10.​1634/​theoncologist.​2010-0156 .PubMedCentral CrossRef PubMed
  7.Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012;118(7):1764–73. doi:10.​1002/​cncr.​26500 .CrossRef PubMed
  8.Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381(9871):1058–69. doi:10.​1016/​S0140-6736(13)60109-9 .PubMedCentral CrossRef PubMed
  9.Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 2005;63(5):588–93. doi:10.​1111/​j.​1365-2265.​2005.​02389.​x .CrossRef
  10.Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003;22(41):6455–7. doi:10.​1038/​sj.​onc.​1206739 .CrossRef PubMed
  11.Cho U, Oh WJ, Bae JS, Lee S, Lee YS, Park GS, et al. Clinicopathological features of rare BRAF mutations in Korean thyroid cancer patients. J Korean Med Sci. 2014;29(8):1054–60. doi:10.​3346/​jkms.​2014.​29.​8.​1054 .PubMedCentral CrossRef PubMed
  12.Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12(2):245–62. doi:10.​1677/​erc.​1.​0978 .CrossRef PubMed
  13.Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90(12):6373–9. doi:10.​1210/​jc.​2005-0987 .CrossRef PubMed
  14.Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54. doi:10.​1038/​nature00766 .CrossRef PubMed
  15.Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ, Lee NS, et al. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg. 2012;203(4):436–41. doi:10.​1016/​j.​amjsurg.​2011.​02.​013 .CrossRef PubMed
  16.Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J. 2009;56(1):89–97.CrossRef PubMed
  17.Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4:2185. doi:10.​1038/​ncomms3185 .CrossRef PubMed
  18.Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32(25):2718–26. doi:10.​1200/​JCO.​2014.​55.​5094 .PubMedCentral CrossRef PubMed
  19.Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339(6122):959–61. doi:10.​1126/​science.​1230062 .CrossRef PubMed
  20.Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M. Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle. 2013;12(10):1637–8. doi:10.​4161/​cc.​24662 .PubMedCentral CrossRef PubMed
  21.Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20(4):603–10. doi:10.​1530/​erc-13-0210 .PubMedCentral CrossRef PubMed
  22.Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz Jr LA, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110(15):6021–6. doi:10.​1073/​pnas.​1303607110 .PubMedCentral CrossRef PubMed
  23.Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339(6122):957–9. doi:10.​1126/​science.​1229259 .PubMedCentral CrossRef PubMed
  24.Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014;99(5):E754–65. doi:10.​1210/​jc.​2013-3734 .PubMedCentral CrossRef PubMed
  25.Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, et al. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. 2014;33(42):4978–84. doi:10.​1038/​onc.​2013.​446 .CrossRef PubMed
  26.Chou A, Fraser S, Toon CW, Clarkson A, Sioson L, Farzin M, et al. A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. Am J Surg Pathol. 2015;39(5):652–9. doi:10.​1097/​pas.​0000000000000368​ .PubMedCentral CrossRef PubMed
  27.Demeure MJ, Aziz M, Rosenberg R, Gurley SD, Bussey KJ, Carpten JD. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target. World J Surg. 2014;38(6):1296–305. doi:10.​1007/​s00268-014-2485-3 .CrossRef PubMed
  28.Kelly LM, Barila G, Liu P, Evdokimova VN, Trivedi S, Panebianco F, et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A. 2014;111(11):4233–8. doi:10.​1073/​pnas.​1321937111 .PubMedCentral CrossRef PubMed
  29.Park G, Kim TH, Lee HO, Lim JA, Won JK, Min HS, et al. Standard immunohistochemistry efficiently screens for anaplastic lymphoma kinase rearrangements in differentiated thyroid cancer. Endocr Relat Cancer. 2015;22(1):55–63. doi:10.​1530/​erc-14-0467 .CrossRef PubMed
  30.Perot G, Soubeyran I, Ribeiro A, Bonhomme B, Savagner F, Boutet-Bouzamondo N, et al. Identification of a recurrent STRN/ALK fusion in thyroid carcinomas. PLoS One. 2014;9(1):e87170. doi:10.​1371/​journal.​pone.​0087170 .PubMedCentral CrossRef PubMed
  31.McFadden DG, Dias-Santagata D, Sadow PM, Lynch KD, Lubitz C, Donovan SE, et al. Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2014;99(11):E2457–62. doi:10.​1210/​jc.​2014-2611 .PubMedCentral CrossRef PubMed
  32.Network TCGAR. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676–90. doi:10.​1016/​j.​cell.​2014.​09.​050 .CrossRef
  33.Oh WJ, Lee YS, Cho U, Bae JS, Lee S, Kim MH, et al. Classic papillary thyroid carcinoma with tall cell features and tall cell variant have similar clinicopathologic features. Korean J Pathol. 2014;48(3):201–8. doi:10.​4132/​KoreanJPathol.​2014.​48.​3.​201 .PubMedCentral CrossRef PubMed
  34.Jung CK, Im SY, Kang YJ, Lee H, Jung ES, Kang CS, et al. Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma. Thyroid. 2012;22(8):791–7. doi:10.​1089/​thy.​2011.​0123 .CrossRef PubMed
  35.Liu T, Brown TC, Juhlin CC, Andreasson A, Wang N, Backdahl M, et al. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocr Relat Cancer. 2014;21(3):427–34. doi:10.​1530/​erc-14-0016 .PubMedCentral CrossRef PubMed
  36.Sabra MM, Dominguez JM, Grewal RK, Larson SM, Ghossein RA, Tuttle RM, et al. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab. 2013;98(5):E829–36. doi:10.​1210/​jc.​2012-3933 .PubMedCentral CrossRef PubMed
  37.Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013;98(9):E1562–6. doi:10.​1210/​jc.​2013-2383 .PubMedCentral CrossRef PubMed
  38.Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab. 2014;99(6):E1130–6. doi:10.​1210/​jc.​2013-4048 .PubMedCentral CrossRef PubMed
  39.Dettmer MS, Schmitt A, Steinert H, Capper D, Moch H, Komminoth P, et al. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. Endocr Relat Cancer. 2015;22(3):419–29. doi:10.​1530/​erc-15-0057 .CrossRef PubMed
  40.Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A, Sancisi V. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. Eur J Endocrinol. 2015;172(4):403–13. doi:10.​1530/​eje-14-0837 .CrossRef PubMed
  41.Muzza M, Colombo C, Rossi S, Tosi D, Cirello V, Perrino M, et al. Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. Mol Cell Endocrinol. 2015;399:288–95. doi:10.​1016/​j.​mce.​2014.​10.​019 .CrossRef PubMed
  42.Qasem E, Murugan AK, Al-Hindi H, Xing M, Almohanna M, Alswailem M, et al. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population. Endocr Relat Cancer. 2015;22(6):901–8. doi:10.​1530/​erc-15-0396 .CrossRef PubMed
  43.Shi X, Liu R, Qu S, Zhu G, Bishop J, Liu X, et al. Association of TERT promoter mutation 1,295,228 C > T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2015;100(4):E632–7. doi:10.​1210/​jc.​2014-3606 .CrossRef PubMed
  44.Yu XM, Schneider DF, Leverson G, Chen H, Sippel RS. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases. Thyroid. 2013;23(10):1263–8. doi:10.​1089/​thy.​2012.​0453 .PubMedCentral CrossRef PubMed
  45.Hong AR, Lim JA, Kim TH, Choi HS, Yoo WS, Min HS, et al. The frequency and clinical implications of the BRAF(V600E) mutation in papillary thyroid cancer patients in Korea over the past two decades. Endocrinol Metab (Seoul). 2014;29(4):505–13. doi:10.​3803/​EnM.​2014.​29.​4.​505 .CrossRef
  46.Pillai S, Gopalan V, Smith RA, Lam AK. Diffuse sclerosing variant of papillary thyroid carcinoma--an update of its clinicopathological features and molecular biology. Crit Rev Oncol Hematol. 2015;94(1):64–73. doi:10.​1016/​j.​critrevonc.​2014.​12.​001 .CrossRef PubMed
  47.Zhang Z, Liu D, Murugan AK, Liu Z, Xing M. Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocr Relat Cancer. 2014;21(2):161–73. doi:10.​1530/​erc-13-0399 .PubMedCentral CrossRef PubMed
  48.Yang K, Wang H, Liang Z, Liang J, Li F, Lin Y. BRAFV600E mutation associated with non-radioiodine-avid status in distant metastatic papillary thyroid carcinoma. Clin Nucl Med. 2014;39(8):675–9. doi:10.​1097/​rlu.​0000000000000498​ .CrossRef PubMed
  49.Huang DS, Wang Z, He XJ, Diplas BH, Yang R, Killela PJ, et al. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer. 2015;51(8):969–76. doi:10.​1016/​j.​ejca.​2015.​03.​010 .PubMedCentral CrossRef PubMed
  
• 作者单位：Ja Seong Bae (1)
  Yourha Kim (2) (3)
  Sora Jeon (2) (3)
  Se Hee Kim (2)
  Tae Jung Kim (2)
  Sohee Lee (1)
  Min-Hee Kim (4)
  Dong Jun Lim (4)
  Youn Soo Lee (1)
  Chan Kwon Jung (2)
  
  1. Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea
  2. Department of Hospital Pathology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul, 06591, Republic of Korea
  3. Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea
  4. Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea
  
• 刊物主题：Pathology;
• 出版者：BioMed Central
• ISSN：1746-1596

文摘

Background Mutations in the TERT promoter, ALK rearrangement, and the BRAF V600E mutation are associated with aggressive clinicopathologic features in thyroid cancers. However, little is known about the impact of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of BRAF mutations.